Professor Bryan Lynch:

I agree it is a strange situation. I have no control over what products have been applied for and approved through the MCAP. What I want very clearly is a pure CBD product. The HSE guidelines document which came out of our committee review very clearly stated that is what we wanted for epilepsy. While I am not an expert on legislation and on the niceties of what can and cannot be submitted, the MCAP, as set up, seems to be designed for products which contain a component of THC, and that is a problem that we have at present. None of it is of my desire or making. I want to be able to prescribe a pure CBD product for my patients and I want it as soon as possible.